Efficacy of Venetoclax plus Rituximab for Relapsed CLL: 5-Year Follow-Up of Continuous or Limited- Duration Therapy

The authors reported long-term follow-up of the Phase Ib study of venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL), including outcomes with continuous or limited-duration therapy.